Nkarta, Inc. (NKTX)

Market Cap	520.76M
Revenue (ttm)	n/a
Net Income (ttm)	-117.50M
Shares Out	70.47M
EPS (ttm)	-2.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	786,971
Open	7.25
Previous Close	7.29
Day's Range	7.19 - 7.63
52-Week Range	1.28 - 16.24
Beta	0.71
Analysts	Strong Buy
Price Target	17.86 (+141.68%)
Earnings Date	May 9, 2024

About NKTX

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical tr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 10, 2020
• Employees: 150
• Stock Exchange: NASDAQ
• Ticker Symbol: NKTX

Analyst Forecast

According to 7 analysts, the average rating for NKTX stock is "Strong Buy." The 12-month stock price forecast is $17.86, which is an increase of 141.68% from the latest price.

Price Target

$17.86

(141.68% upside)

Analyst Consensus: Strong Buy